Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1987-2-19
|
| pubmed:abstractText |
Forty-two evaluable patients with advanced non-small cell lung cancer were treated with teniposide at doses ranging from 120 to 180 mg/m2 on Days 1, 3, and 5 every 3 weeks. Thirty-four patients had received no prior chemotherapy. Seven partial responses (16.6%) were obtained (21% in chemotherapy-unexposed patients). Marrow toxicity was the main side effect: life-threatening thrombocytopenia occurred in 9% of patients, and 54.5% experienced severe leukopenia. Teniposide, at the doses and schedule employed, has moderate activity in non-small cell lung cancer.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0361-5960
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
71
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
83-5
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:3024829-Adult,
pubmed-meshheading:3024829-Aged,
pubmed-meshheading:3024829-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:3024829-Drug Evaluation,
pubmed-meshheading:3024829-Female,
pubmed-meshheading:3024829-Humans,
pubmed-meshheading:3024829-Lung Neoplasms,
pubmed-meshheading:3024829-Male,
pubmed-meshheading:3024829-Middle Aged,
pubmed-meshheading:3024829-Podophyllotoxin,
pubmed-meshheading:3024829-Teniposide
|
| pubmed:year |
1987
|
| pubmed:articleTitle |
Teniposide in the treatment of non-small cell lung carcinoma.
|
| pubmed:publicationType |
Journal Article
|